Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita & Toshihiko Torigoe. (2022) Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. Immunological Medicine 45:2, pages 108-118.
Read now
Read now
Remo Poto, Giancarlo Marone, Flora Pirozzi, Maria Rosaria Galdiero, Alessandra Cuomo, Luigi Formisano, Roberto Bianco, Carminia Maria Della Corte, Floriana Morgillo, Stefania Napolitano, Teresa Troiani, Carlo G Tocchetti, Valentina Mercurio & Gilda Varricchi. (2021) How can we manage the cardiac toxicity of immune checkpoint inhibitors?. Expert Opinion on Drug Safety 20:6, pages 685-694.
Read now
Read now
Laila Belcaid, Soizic Garaud, Joseph Kerger, Sideris Spyridon & Sandrine Aspeslagh. (2021) Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. Acta Clinica Belgica 76:2, pages 144-148.
Read now
Read now
Michael G McCusker, Dennis Orkoulas-Razis & Ranee Mehra. (2020) Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date. OncoTargets and Therapy 13, pages 3047-3059.
Read now
Read now
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, Sabine Tejpar, Peter Vandenberghe, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2020) Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology 9:1.
Read now
Read now
Sang T. Kim & Maria E. Suarez-Almazor. (2019) Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. Expert Review of Clinical Immunology 15:3, pages 211-213.
Read now
Read now
Articles from other publishers (49)
Mutsumi Ozasa, Junya Fukuoka & Maxwell L. Smith. 2024. Practical Pulmonary Pathology. Practical Pulmonary Pathology
231
302
.
Taehoon Kim, Hyeonseob Lim, Soyeong Jun, Junsik Park, Dongin Lee, Ji Hyun Lee, Jung-Yun Lee & Duhee Bang. (2023) Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer. Scientific Reports 13:1.
Crossref
Crossref
A. D. Koltakova & A. M. Lila. (2023) Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem. Modern Rheumatology Journal 17:5, pages 112-117.
Crossref
Crossref
Xiao Hu, Jin Ren, Qianfei Xue, Rumei Luan, Dongyan Ding, Jie Tan, Xin Su & Junling Yang. (2023) Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review). International Journal of Oncology 63:5.
Crossref
Crossref
Wei Zhang, Yifei Tan, Yuquan Li & Jiang Liu. (2023) Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Frontiers in Immunology 14.
Crossref
Crossref
Woorim Kim, Young Ah Cho, Kyung Hyun Min, Dong-Chul Kim & Kyung-Eun Lee. (2023) Machine Learning Approaches for Assessing Risk Factors of Adrenal Insufficiency in Patients Undergoing Immune Checkpoint Inhibitor Therapy. Pharmaceuticals 16:8, pages 1097.
Crossref
Crossref
Nika Guberina, Florian Wirsdörfer, Martin Stuschke & Verena Jendrossek. (2023) Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis – The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. Neoplasia 39, pages 100892.
Crossref
Crossref
Yong-Qiang Ao, Jian Gao, Shuai Wang, Jia-Hao Jiang, Jie Deng, Hai-Kun Wang, Bei Xu & Jian-Yong Ding. (2023) Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Molecular Cancer 22:1.
Crossref
Crossref
Xiangxiao Hu, Lina Wang, Bin Shang, Junren Wang, Jian Sun, Bin Liang, Lili Su, Wenjie You & Shujuan Jiang. (2023) Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. Frontiers in Immunology 14.
Crossref
Crossref
Lei Pan, Fanqi Meng, Wei Wang, Xu-hao Wang, Hui Shen, Pengchen Bao, Jian Kang & Delei Kong. (2023) Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Frontiers in Immunology 13.
Crossref
Crossref
Pierre Van Mol, Elena Donders, Diether Lambrechts & Els Wauters. 2023.
Alice Tison, Soizic Garaud, Laurent Chiche, Divi Cornec & Marie Kostine. (2022) Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nature Reviews Rheumatology 18:11, pages 641-656.
Crossref
Crossref
Yanni Wang, Jianling Zou, Yun Li, Xi Jiao, Yujiao Wang, Na Zhuo, Mengting Gao, Jifang Gong, Jian Li, Xiaotian Zhang, Xicheng Wang, Zhi Peng, Changsong Qi, Zhenghang Wang, Jie Li, Yan Li, Lin Shen, Henghui Zhang & Zhihao Lu. (2022) Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers. Frontiers in Immunology 13.
Crossref
Crossref
Amelie Franken, Pierre Van Mol, Sam Vanmassenhove, Elena Donders, Rogier Schepers, Thomas Van Brussel, Christophe Dooms, Jonas Yserbyt, Nico De Crem, Dries Testelmans, Walter De Wever, Kristiaan Nackaerts, Johan Vansteenkiste, Robin Vos, Stéphanie Humblet-Baron, Diether Lambrechts & Els Wauters. (2022) Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. Journal for ImmunoTherapy of Cancer 10:9, pages e005323.
Crossref
Crossref
Xiao Zhou, Xiang Chen, Leng Han & Hong Liu. (2022) Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. Clinical Science 136:10, pages 771-785.
Crossref
Crossref
Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang & Roza Nurieva. (2022) Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 13:1.
Crossref
Crossref
Zengfu Zhang, Jialin Zhou, Vivek Verma, Xu Liu, Meng Wu, Jinming Yu & Dawei Chen. (2021) Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury. Frontiers in Immunology 12.
Crossref
Crossref
Valerio Nardone, Rocco Giannicola, Diana Giannarelli, Rita Emilena Saladino, Domenico Azzarello, Caterina Romeo, Giovanna Bianco, Maria Rosaria Rizzo, Irene Di Meo, Antonio Nesci, Pierpaolo Pastina, Antonia Consuelo Falzea, Daniele Caracciolo, Alfonso Reginelli, Michele Caraglia, Amalia Luce, Luciano Mutti, Antonio Giordano, Salvatore Cappabianca, Luigi Pirtoli, Vito Barbieri, Pierfrancesco Tassone, Pierosandro Tagliaferri & Pierpaolo Correale. (2021) Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. Life 11:11, pages 1235.
Crossref
Crossref
Kentaro Yamada, Tsunaki Sawada, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Eri Ishikawa, Tadashi Iida, Yasuyuki Mizutani, Naomi Kakushima, Takuya Ishikawa, Kazuhiro Furukawa, Eizaburo Ohno, Takashi Honda, Hiroki Kawashima, Masatoshi Ishigami, Satoshi Furune, Tetsunari Hase, Kenji Yokota, Osamu Maeda, Naozumi Hashimoto, Masashi Akiyama, Yuichi Ando & Mitsuhiro Fujishiro. (2021) Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. World Journal of Gastroenterology 27:41, pages 7190-7206.
Crossref
Crossref
Hiroyuki Ando, Kunihiro Suzuki & Toyoshi Yanagihara. (2021) Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. Biomedicines 9:10, pages 1484.
Crossref
Crossref
Carolina A. Ferreira, Pedram Heidari, Bahar Ataeinia, Nicoleta Sinevici, Meghan E. Sise, Robert B. Colvin, Eric Wehrenberg-Klee & Umar Mahmood. (2021) Non-invasive Detection of Immunotherapy-Induced Adverse Events. Clinical Cancer Research 27:19, pages 5353-5364.
Crossref
Crossref
Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Ernest Nadal, Yago Garitaonaindía, Amelia Insa, Joaquín Mosquera, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodriguez-Abreu, Alex Martinez-Marti, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massuti, Raquel Laza-Briviesca, Marta Casarrubios, Aránzazu García-Grande, Atocha Romero, Fernando Franco & Mariano Provencio. (2021) Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. Journal for ImmunoTherapy of Cancer 9:8, pages e002804.
Crossref
Crossref
David J. Lee, Howard J. LeeJrJr, Jocelyn R. Farmer & Kerry L. Reynolds. (2021) Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Cardiology Reports 23:8.
Crossref
Crossref
Hao Nie, Ting Chen, Kefei He, Chanjin Liang, Wei Guo & Xingyuan Shi. (2021) Immunotherapy-Based Therapeutic Strategies for Recurrent Advanced Squamous Cell Carcinoma of the Head and Neck: A Case Report and Literature Review. Frontiers in Immunology 12.
Crossref
Crossref
Tricia Cottrell, Jiajia Zhang, Boyang Zhang, Genevieve J Kaunitz, Poromendro Burman, Hok-Yee Chan, Franco Verde, Jody E Hooper, Hans Hammers, Mohamad E Allaf, Hongkai Ji, Janis Taube & Kellie N Smith. (2021) Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance. Journal for ImmunoTherapy of Cancer 9:7, pages e002642.
Crossref
Crossref
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson, Mario E Lacouture, Gregory A Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D Santomasso, Satish P Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A Sosman, Michelle Turner & Marc S Ernstoff. (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer 9:6, pages e002435.
Crossref
Crossref
Qin Zhang, Liansha Tang, Yuwen Zhou, Wenbo He & Weimin Li. (2021) Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. Frontiers in Immunology 12.
Crossref
Crossref
Yong Fan, Yan Geng, Lin Shen & Zhuoli Zhang. (2020) Advances on immune-related adverse events associated with immune checkpoint inhibitors. Frontiers of Medicine 15:1, pages 33-42.
Crossref
Crossref
David König & Heinz Läubli. (2021) Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology 106:3-4, pages 123-136.
Crossref
Crossref
Xiaoxiang Zhou, Zhuoran Yao, Huaxia Yang, Naixin Liang, Xuan Zhang & Fengchun Zhang. (2020) Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Medicine 18:1.
Crossref
Crossref
Shicong Zhu, Yang Fu, Bo Zhu, Bicheng Zhang & Jun Wang. (2020) Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. Frontiers in Oncology 10.
Crossref
Crossref
Brendan L. Mangan, Renee K. McAlister, Justin M. Balko, Douglas B. Johnson, Javid J. Moslehi, Andrew Gibson & Elizabeth J. Phillips. (2020) Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. British Journal of Clinical Pharmacology 86:9, pages 1778-1789.
Crossref
Crossref
Michael D. Richter, Grant C. Hughes, Sarah H. Chung, Mary Ezeanuna, Namrata Singh & John A. Thompson. (2020) Immunologic adverse events from immune checkpoint therapy. Best Practice & Research Clinical Rheumatology 34:4, pages 101511.
Crossref
Crossref
Kunihiro Suzuki, Toyoshi Yanagihara, Koichiro Matsumoto, Hitoshi Kusaba, Takuji Yamauchi, Yuki Ikematsu, Kentaro Tanaka, Kohei Otsubo, Hiroyuki Inoue, Yasuto Yoneshima, Eiji Iwama, Masako Arimura-Omori, Eiji Harada, Naoki Hamada, Isamu Okamoto & Yoichi Nakanishi. (2020) Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. International Immunology 32:8, pages 547-557.
Crossref
Crossref
Joshua E. Reuss, Karthik Suresh & Jarushka Naidoo. (2020) Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Current Oncology Reports 22:6.
Crossref
Crossref
Teppei Sugano, Masahiro Seike, Yoshinobu Saito, Takeru Kashiwada, Yasuhiro Terasaki, Natsuki Takano, Kakeru Hisakane, Satoshi Takahashi, Toru Tanaka, Susumu Takeuchi, Akihiko Miyanaga, Yuji Minegishi, Rintaro Noro, Kaoru Kubota & Akihiko Gemma. (2020) Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer. Thoracic Cancer 11:4, pages 1052-1060.
Crossref
Crossref
Huaxia Yang, Zhuoran Yao, Xiaoxiang Zhou, Wen Zhang, Xuan Zhang & Fengchun Zhang. (2020) Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clinical Immunology 213, pages 108377.
Crossref
Crossref
Rhiane Moody, Kirsty Wilson, Anthony Jaworowski & Magdalena Plebanski. (2020) Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. Cancers 12:3, pages 673.
Crossref
Crossref
Leonard H. Calabrese & Cassandra Calabrese. (2020) The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. Current Opinion in Rheumatology 32:2, pages 175-183.
Crossref
Crossref
Beckey Trinh, Guacimara Ortega Sanchez, Petra Herzig & Heinz Läubli. (2019) Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Jocelyn R. Farmer. (2019) Testing Immune-Related Adverse Events in Cancer Immunotherapy. Clinics in Laboratory Medicine 39:4, pages 669-683.
Crossref
Crossref
Mengqian Li, Lu Gan, Andrew Song, Jianxin Xue & You Lu. (2019) Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1871:2, pages 323-330.
Crossref
Crossref
Viktor H. Koelzer, Korsuk Sirinukunwattana, Jens Rittscher & Kirsten D. Mertz. (2018) Precision immunoprofiling by image analysis and artificial intelligence. Virchows Archiv 474:4, pages 511-522.
Crossref
Crossref
Heinz Läubli, Stefan Dirnhofer & Alfred Zippelius. (2018) Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv 474:4, pages 485-495.
Crossref
Crossref
Heinz Läubli, Catharina Balmelli, Lukas Kaufmann, Michal Stanczak, Mohammedyaseen Syedbasha, Dominik Vogt, Astrid Hertig, Beat Müller, Oliver Gautschi, Frank Stenner, Alfred Zippelius, Adrian Egli & Sacha I. Rothschild. (2018) Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Leonard H. Calabrese, Cassandra Calabrese & Laura C. Cappelli. (2018) Rheumatic immune-related adverse events from cancer immunotherapy. Nature Reviews Rheumatology 14:10, pages 569-579.
Crossref
Crossref
Kentaro Tanaka, Toyoshi Yanagihara, Yuki Ikematsu, Hiroyuki Inoue, Keiichi Ota, Eiji Kashiwagi, Kunihiro Suzuki, Naoki Hamada, Ario Takeuchi, Katsunori Tatsugami, Masatoshi Eto, Kayo Ijichi, Yoshinao Oda, Kohei Otsubo, Yasuto Yoneshima, Eiji Iwama, Yoichi Nakanishi & Isamu Okamoto. (2018) Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget 9:55, pages 30587-30593.
Crossref
Crossref
Adel Gazizova, Andrey Zolotarev, Vladislav Myrov, Anastasiya Vinogradova, Aleksandr Cheblokov, Evgeny Bakin & Oksana Stanevich. (2018) Open Source Tool for VH-replacement Products Discovery and Analysis. Open Source Tool for VH-replacement Products Discovery and Analysis.
. (2018) Nivolumab/pembrolizumab. Reactions Weekly 1685:1, pages 155-155.
Crossref
Crossref